Pfizer Is Worst-Performing US Large-Cap Pharma Stock This Year, Its Investment Case Is Complex Yet Rewarding

  • Credit Suisse has initiated coverage on Pfizer Inc PFE with an Outperform rating and a price target of $55.
  • The analyst says that Pfizer has been the worst-performing U.S. Large-Cap Pharma this year, falling 15% on uncertainties with COVID-19 and slowing vaccine sales. 
  • Heading into 2023, Credit Suisse thinks 2023 forecasts for COVID-19 products remain uncertain, and it is difficult to see a meaningful catalyst to reverse this share price decline. 
  • Related: Pfizer's Q3 Earnings Surpasses Estimates, Lifts Forecasts For COVID-19 Vaccine Sales By $2B.
  • The analyst says the strength of Pfizer's base business is underestimated, where a consistent cadence of smaller, positive pipeline events combined should accelerate growth. 
  • Higher long-term COVID vaccine sales would augment this at a commercial price, an overlooked pipeline, and expected business development deals. Credit Suisse views valuation as undemanding, especially after this year, with the target price implying a 13% upside potential to the current price.
  • Price Action: PFE shares are down 0.72% at $47.98 on the last check Friday.
  • Image by x3 from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechLarge CapNewsHealth CareInitiationTop StoriesAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!